Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers

Roberta Sanfilippo, Federica Grosso, Robin L. Jones, Susana Banerjee, Silvana Pilotti, Maurizio D'Incalci, Angelo Paolo Dei Tos, Francesco Raspagliesi, Ian Judson, Paolo Giovanni Casali

Research output: Contribution to journalArticlepeer-review


Background: Treatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma. Patients and methods: A retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed. Results: Sixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1-5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2-5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively. Conclusions: Trabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient.

Original languageEnglish
Pages (from-to)553-556
Number of pages4
JournalGynecologic Oncology
Issue number3
Publication statusPublished - Dec 2011


  • Chemotherapy
  • Leiomyosarcoma
  • Soft tissue sarcoma
  • Trabectedin
  • Uterine neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers'. Together they form a unique fingerprint.

Cite this